Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. RESULTS: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. CONCLUSIONS: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.19”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [19]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationManual of Clinical Laboratory Immunology
Rose, N. R., Hamilton, R. G., & Detrick, B. (1992) · Cited by 1,250
Cited by
Items 501–600 of 932
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review
Kakkilaya, A., Trando, A., Cliff, E. R. S., Mian, H. S., Hadidi, S. A., Aziz, M., Goodman, A. M., Jeong, A., Lee‐Smith, W., Kelkar, A. H., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae219 · Cited by 8
Kozlowska, D., Biswas, S., Fox, E. K., Wu, B. H., Bolster, F., Edupuganti, O. P., Torchilin, V. P., Eustace, S. J., Botta, M., O’Kennedy, R. J., et al. (2014) · RSC Advances · doi:10.1039/c3ra45400b · Cited by 8
Monoclonal Gammopathy of Undetermined Significance
Go, R. S., Heien, H. C., Sangaralingham, L. R., Habermann, E. B., & Shah, N. D. (2017) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2017.06.002 · Cited by 9
Tanaka, T., Fuga, M., Teshigawara, A., Hasegawa, Y., Nishiwaki, K., Murayama, Y., & Yokoo, H. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.07.212 · Cited by 8
Sessa, M., Cavazzini, F., Cavallari, M., Rigolin, G. M., & Cuneo, A. (2020) · Genes · doi:10.3390/genes11121453 · Cited by 8
Vasco-Mogorrón, M. A., Campillo, J. A., Periago, A., Cabañas, V., Berenguer, M., García-Garay, M. C., Gimeno, L., Soto‐Ramírez, M. F., Martínez-Hernández, M. D., Muro, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083895 · Cited by 8
“Although the progression rates to MM in asymptomatic MGUS and SMM are about 1% and 10% per year, respectively [11,12], prognostic biomarkers are also needed in MGUS and SMM for counseling, clinical care, and follow-up, and for the design of clinical studies in patients at high risk [9].”
BackgroundChakraborty, R. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.041 · Cited by 8
Monoclonal Gammopathy and Smoldering Multiple Myeloma: Diagnosis, Staging, Prognosis, Management
Hillengaß, J., Moehler, T. M., & Hundemer, M. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_6 · Cited by 9
“Kyle et al. investigated a cohort of 276 patients with sMM and 163 patients (59%) developed symptomatic multiple myeloma or AL-amyloidosis during follow-up ( Kyle et al. 2007 ).”
BackgroundMultiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
Self-citationHubbard, J. W., Locke, K. W., Forster, H. V., Brice, A. G., Pan, L. G., Lowry, T. F., Forster, A. M., Forster, M. A., Cornfeldt, M. L., & Vanselous, C. L. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11439-0 · Cited by 9
Tuckey, N., Iasiello, M. P., Ali, K., Yong, A., Wilson, S., Ryan, M., Scoleri, D., Cantley, M. D., & Wardill, H. R. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.09.016 · Cited by 7
Cogrossi, L. L., Policastro, A., Zordan, P., Grioni, M., Tosi, A., RIZZO, N., Mattorre, B., Lorenzoni, M., Meregalli, G., Sisti, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65312-y · Cited by 8
Rajkumar, S. V., Mateos, M., Schaeffer, M., Lin, X., Bathija, S., Gupta‐Werner, N., Lam, A., Carson, R. L., Dennis, R. M., Kaila, S., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01170-z · Cited by 7
Self-citationRole of Imaging in Multiple Myeloma: A Potential Opportunity for Quantitative Imaging and Radiomics?
Michalska, A., Rogowska, A., Kwiatkowska-Miernik, A., Sklinda, K., Mruk, B., Hus, I., & Walecki, J. M. (2024) · Cancers · doi:10.3390/cancers16234099 · Cited by 8
Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders
Manier, S., Salem, K. Z., Liu, D., & Ghobrial, I. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159010 · Cited by 8
Yu, C. Y., Xiang, S., Huang, Z., Johnson, T. S., Zhan, X., Han, Z., Zaid, M. I. A., & Huang, K. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00468 · Cited by 7
Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard
Fonseca, R., & González-Vélez, M. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280179 · Cited by 7
Self-citationPET Imaging for Hematologic Malignancies
Hughes, N., & Jacene, H. A. (2021) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2021.05.003 · Cited by 7
A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma
Zhang, B., Wang, Q., Lin, Z., Zheng, Z., Zhou, S., Zhang, T., Zheng, D., Chen, Z., Zheng, S., Zhang, Y., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1198949 · Cited by 8
“MM is a highly heterogenous disease, that exits on a continuous disease spectrum ranging from precancerous states monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) driven by the accumulating genetic changes and immune escape (Kyle et al., 2002; Kyle et al., 2007; Landgren…”
BackgroundFeyereisn, W. L., Fenstad, E. R., McCully, R. B., & Lacy, M. Q. (2015) · Pulmonary Circulation · doi:10.1086/679726 · Cited by 7
“8 years with the greatest overall risk of progression in the first 5 years (10% per year).(11) Recently, a randomized trial of 119 patients with high-risk SMM investigated disease progression and outcomes of early treatment with lenalidomide and dexamethasone.”
BackgroundExercise Is Medicine: Case Report of a Woman with Smoldering Multiple Myeloma
Boullosa, D. A., ABREU, L., Tonello, L., Hofmann, P., & Leicht, A. S. (2013) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3182880359 · Cited by 9
“MM is preceded by monoclonal gammopathy of undetermined significance (MGUS) and/or smoldering multiple myeloma (SMM), which are asymptomatic precursor conditions (22).”
BackgroundInfluentialCocito, F., Mangiacavalli, S., Ferretti, V. V., Cartia, C. S., Ganzetti, M., Benveuti, P., Pompa, A., Catalano, M., Fugazza, E., Landini, B., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1620948 · Cited by 7
“Among others, the first Mayo prognostic score from 2007 has the advantage of requiring very simple parameters, quite always available in clinical practice (BMPC together with serum MC) [5].”
BackgroundResultInfluentialIdentifying monoclonal gammopathy of undetermined significance in electronic health data
Epstein, M. M., Saphirak, C., Zhou, Y., Leblanc, C., Rosmarin, A. G., Ash, A. S., Singh, S., Fisher, K. A., Birmann, B. M., & Gurwitz, J. H. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4912 · Cited by 7
Increased expression of IFI16 predicts adverse prognosis in multiple myeloma
Huang, W., Qian, T., Huang, Z., Liu, Y., Cui, L., Zhu, P., Zhong, Q., Zeng, T., Fu, L. N., Si, C., et al. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-021-00230-y · Cited by 7
Omar, N., Madwani, K., Moideen, P., Manthei, D. M., Keren, D. F., & Singh, G. (2021) · Laboratory Medicine · doi:10.1093/labmed/lmab055 · Cited by 7
Musso, N., Romano, A., Bonacci, P. G., Scandura, G., Pandino, C., Camarda, M., Russo, G. I., Raimondo, F. D., Cacciola, E., & Cacciola, R. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231912052 · Cited by 7
“Multiple myeloma (MM) is a blood clonal B-cell malignancy due to an uncontrolled proliferation of plasma cancer cells (PCs) in the bone marrow (BM) or, more rarely, in extramedullary tissues, which is characterized by the presence of a monoclonal component (M protein) in serum and/or urine, composed of immunoglobulins…”
BackgroundA descriptive study of plasma cell dyscrasias in Egyptian population
Kassem, N. M. A., Zawam, H. E., Kassem, H. A., Nahas, T. I. H. E., Husseiny, N. M. E., & Azeeim, H. A. E. (2013) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2013.09.002 · Cited by 7
“In some patients, an intermediate asymptomatic but more advanced premalignant stage, referred to as ‘‘smoldering multiple myeloma’’, is clinically recognized [6].”
BackgroundGhobrial, I. M. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.788699 · Cited by 7
Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults
Guerard, E. J., & Tuchman, S. A. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.08.012 · Cited by 7
“Patients with SMM should be monitored at 2 to 3 months after the diagnosis and then every 4 to 6 months with an HP and laboratory testing.(25) There are several therapies currently under investigation to prevent or delay progression to symptomatic MM,(26) but standard of care in the United States arguably remains obse…”
BackgroundMethodInfluentialTiming of treatment of smoldering myeloma: delay until progression
Kumar, S. K. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018021238 · Cited by 7
“Longterm follow-up of patients with SMM has clearly shown that nearly half of patients do not progress in the first 5 years, and more importantly, one-third of patients remain progression-free at 10 years and have a progression risk that is comparable to MGUS (ie, 1% per year).(2,9) Such a strategy will clearly lead t…”
BackgroundMethodHow We Approach Smoldering Multiple Myeloma
Raje, N. S., & Yee, A. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02834 · Cited by 7
“The cumulative probability of progression from SMM to MM is 73% at 15 years.(5) There is debate as to whether SMM is a condition to be treated as an early stage of MM(6) or simply observed, as with MGUS.”
BackgroundMultiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities
Landgren, O. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.11.008 · Cited by 7
Diagnosis, risk stratification and management of smouldering multiple myeloma
Zanwar, S., Kumar, S. K., & Rajkumar, S. V. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01119-0 · Cited by 8
Self-citationBorges, G. Á., Diaz‐delCastillo, M., Guilatco, A. J., El-Masri, B. M., Mustapha, F., Gundesen, M. T., Hinge, M., Lund, T., Abdallah, N. H., Baughn, L. B., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02572-z · Cited by 6
“Stable MGUS and SMM patients were identi fi ed based on the lack of progression to MM ≤ 10 y or 5 y, respectively, following sample collection (Supplemental Table 6).”
Initial Treatment of Nontransplant Patients With Multiple Myeloma
Cerrato, C., & Palumbo, A. P. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.003 · Cited by 6
Managing multiple myeloma in the over 70s: A review
King, A. J., Gooding, S., & Ramasamy, K. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.11.017 · Cited by 7
Parra, M., Baptista, M. J., Genescà, E., Llinàs‐Arias, P., & Esteller, M. (2020) · Hematological Oncology · doi:10.1002/hon.2725 · Cited by 7
“She explained the differential diagnostic criteria of MM, monoclonal gammopathy of uncertain significance (MGUS), and smoldering MM (SMM), pointing out that the overall risk of progression from SMM to MM was 10% per year in the first 5 years.(49) Treatment failure/relapses in MM can be explained by the escape of parti…”
BackgroundNikolaou, A., Hogea, C. S., Samyshkin, Y., Maiese, E. M., Sansbury, L. B., Oguz, M., Cid‐Ruzafa, J., Kapoor, R., & Wang, F. (2022) · Value in Health · doi:10.1016/j.jval.2022.05.011 · Cited by 7
Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review
Ismail, N. H., Mussa, A., Al‐Khreisat, M. J., Yusoff, S. M., Husin, A., & Johan, M. F. (2023) · Diagnostics · doi:10.3390/diagnostics13142328 · Cited by 6
Management of multiple myeloma in resource-constrained settings
Kumar, L., & Sahoo, R. K. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.012 · Cited by 6
“SMM is a heterogeneous disease with variable risk for progression to MM [2]”
BackgroundDiagnosis and Staging of Multiple Myeloma and Related Disorders
Rajkumar, S. V., Fonseca, R., & Miguel, J. F. S. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_2 · Cited by 7
Self-citationA review of epidemiology and management of multiple myeloma in a resource poor country
Akinbami, A., Dosunmu, A. O., & Uche, E. I. (2018) · Annals of Tropical Pathology · doi:10.4103/atp.atp_8_18 · Cited by 6
Progress in the Management of Smoldering Multiple Myeloma
Schmidt, T. M., & Callander, N. S. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00623-7 · Cited by 8
Initial Therapeutic Approaches to Patients with Multiple Myeloma
Berbari, H. E., & Kumar, S. K. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01824-5 · Cited by 6
“MGUS has a low transformation rate at 1–2% per year, while smoldering MM has a 10% chance annually for the first 5 years with a subsequent reduction [3, 4].”
BackgroundChina's potential role in humanitarian assistance
Binder, A., & Conrad, B. (2009) · Cited by 9
Smoldering multiple myeloma: Reviewing the rationale for intervention
Gertz, M. A. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2068008 · Cited by 6
“tiple myeloma, 20% remained free of therapy [3].”
BackgroundMitochondrial dysfunction and drug targets in multiple myeloma
Cui, Y., Wang, F., & Fang, B. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04672-8 · Cited by 7
“SMM proceeds to MM at a rate of 10% per year in the first 5 years and the risk of progression decreases subsequently (Kyle et al. 2007).”
BackgroundA Healthy Young Man Presenting with Multiple Rib Fractures
Harle, L., Chan, C., Bhagavan, N. V., Rios, C. N., Sugiyama, C., Loscalzo, M., Uyehara‐Lock, J. H., & Honda, S. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.135095 · Cited by 6
“IgD-множественная миелома появляется приблизительно в 2% всех случаев миеломы (2, 3).”
Diagnosis and Treatment of Multiple Myeloma
Rajkumar, S. V., & Kyle, R. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_33 · Cited by 6
Self-citationDispenzieri, A. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00079-4 · Cited by 6
Self-citationImaging in multiple myeloma: Computed tomography or magnetic resonance imaging?
Tagliafico, A. S. (2021) · World Journal of Radiology · doi:10.4329/wjr.v13.i7.223 · Cited by 6
Timing treatment for smoldering myeloma: is earlier better?
Hernández‐Rivas, J., Martínez‐López, J., & Lahuerta, J. J. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1599281 · Cited by 5
Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., & Rajkumar, S. V. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_35 · Cited by 5
Self-citationMonoclonal gammopathy detection and current technologies
Hutcherson, S. M., & Thoren, K. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824302-2.00005-9 · Cited by 5
Zhou, P., MANSUKHANI, M. M., Yeh, R., Lu, J., Xia, H., Koganti, L., Pang, J., Toskic, D., Scalia, S., Ma, X., et al. (2024) · British Journal of Cancer Research · doi:10.31488/bjcr.193 · Cited by 5
Magarotto, V., Thevenon, J., Morgan, K., Seldam, S. T., Iraqi, W., Guillaume, X., Leclerc, M., Graziani-Taugeron, C., Rault, B., & Horchi, D. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s453920 · Cited by 6
V. Smoldering multiple myeloma
Mateos, M., & Miguel, J. F. S. (2015) · Hematological Oncology · doi:10.1002/hon.2213 · Cited by 5
“year for the first 5 years, 5% per year during the following 5years and only 1% per year after 10 years [13].”
BackgroundImpact of fire-fighters training on a female with smoldering multiple myeloma.
Boullosa, D. A., Leicht, A. S., & Tuimil, J. L. (2010) · PubMed · Cited by 5
Gao, M., Yang, G., Tompkins, V. S., Gao, L., Wu, X., Yi, T., Hu, X., Hou, J., Han, Y., Xu, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109758 · Cited by 5
“This value exceeds 70% 15 years postdiagnosis [11,12].”
BackgroundMoosig, F., Reinhold‐Keller, E., Holl‐Ulrich, K., Feller, A. C., Bley, T. A., Holle, J. U., Zwerina, J., Lamprecht, P., Dalhoff, K., Venhoff, N., et al. (2012) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-012-0988-6 · Cited by 7
The Road to Treating Smoldering Multiple Myeloma
Korde, N., Mailankody, S., & Landgren, O. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.04.012 · Cited by 5
“The term, SMM, was coined and characterized by Kyle and colleagues and noted to carry an average risk of progressing to malignancy of 10% per year.(4,5) In comparison, monoclonal gammopathy of unknown significance (MGUS) is an asymptomatic plasma cell condition defined as having M-protein < 3 g/dL and < 10% bone marro…”
BackgroundGao, M., Yang, G., Kong, Y., Wu, X., & Shi, J. (2015) · BioMed Research International · doi:10.1155/2015/623254 · Cited by 6
“At the same time, Alexanian et al. use the term indolent multiple myeloma (IMM) in defining 20 patients who were asymptomatic from their low tumor mass disease, had Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 623254, 7 pages…”
BackgroundSmoldering multiple myeloma: present position and potential promises
Tageja, N., Manasanch, E. E., Korde, N., Kwok, M., Mailankody, S., Bhutani, M., Roschewski, M. J., & Landgren, O. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12205 · Cited by 5
“In contrast to MGUS, SMM is more likely to progress to MM, with an average rate of progression of about 10% per year (13).”
Abnormal laboratory results: Screening for multiple myeloma
Firkin, F. C. (2009) · Australian Prescriber · doi:10.18773/austprescr.2009.046 · Cited by 5
Controversies in multiple myeloma: Evidence-based update
Ahn, I. E., & Mailankody, S. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.006 · Cited by 6
Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
Ovejero, S., & Moreaux, J. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00034 · Cited by 8
“Smoldering MM (SMM) is distinguished from MGUS because of a significant increase in the risk of developing MM (10% per year in the first 5 years) [8].”
BackgroundTessier, C., Allard, T., Boudreault, J., Kaedbey, R., Éthier, V., Fortin, F., & Pavic, M. (2021) · Current Oncology · doi:10.3390/curroncol28030188 · Cited by 5
“In contrast, higher BMPC percentage, serum M-protein and FLCr, have consistently been associated with a higher risk of progression [4,14,15,23].”
BackgroundInfluentialA Case of Cast Nephropathy Found as the Cause of Severe Renal Failure
Adachi, G., Mouri, N., Ohta, R., & Sano, C. (2021) · Cureus · doi:10.7759/cureus.19135 · Cited by 5
How to Identify and Manage High-Risk Smoldering Multiple Myeloma
Mouhieddine, T. H. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01596-5 · Cited by 5
“More importantly, the iStopMM and PROMISE studies will provide valuable insights into the natural history of modern SMM cohorts, which differ significantly from those previously studied by Dr. Kyle et al [5].”
InfluentialTikku, G., Jain, M., Mridha, A. R., & Grover, R. K. (2014) · Turkish Journal of Hematology · doi:10.4274/tjh.2012.0167 · Cited by 5
“About 8% of patients with PCM are initially asymptomatic [22].”
BackgroundWang, T., Zhang, Y., Li, Q., Jia, S., Shi, C., Niu, K., & Liu, B. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5244 · Cited by 5
“IgD multiple myeloma represents ~2% of multiple myeloma cases with an incidence of renal involvement of 70% (29).”
Palma, B. D., Marchica, V., Pedrazzoni, M., Accardi, F., Notarfranchi, L., Goldoni, M., Luca, F. D., Costa, F., Storti, P., Toscani, D., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.15026 · Cited by 5
Munshi, N. C., & Jagannath, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00086-x · Cited by 6
Recent Advances in the Management of Smoldering Multiple Myeloma
Madhira, B. R., Konala, V. M., Adapa, S. R., Naramala, S., Ravella, P. M., Parikh, K., & Gentile, T. (2020) · World Journal of Oncology · doi:10.14740/wjon1245 · Cited by 7
“The seminal recognition of SMM came from Kyle and Greipp in 1980, based on a case series of six patients who met the criteria of MM, but showed no evidence of the characteristic clinical CRAB manifestations of sy-MM, nor any progression to sy-MM for 5 or more years [6, 7].”
BackgroundMethodInfluentialMonoclonal Gammopathy of Undetermined Significance
Kyle, R. A., & Rajkumar, S. V. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_38 · Cited by 7
Self-citationSmoldering multiple myeloma: to treat or not to treat
Gentile, M., Offidani, M., Vigna, E., Corvatta, L., Recchia, A. G., Morabito, L., Martino, M. V., Morabito, F., & Gentili, S. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1007952 · Cited by 5
“The Mayo Clinic group, analyzing data from 276 SMM patients, showed that the annual risk of progression to symptomatic MM was 10% per year for the first 5 years, 5% per year during the following 5 years, and 1% per year after the 10th year [3].”
BackgroundMethodImmunoparesis in multiple myeloma: a current overview
Wang, H., & Chen, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1628144 · Cited by 5
Xin, X., Fan, C., Sheng, R., Li, X. C., Zhu, X., Huang, Y., Seraji, H. R., Urazbaeva, D., Atamuratova, Z., & Ubaydullaevna, A. D. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02050-5 · Cited by 4
“Risk of progression averages 10% annually during the first five years, then decreases to 3% and later to 1% [ 32 ].”
Tratamiento del mieloma múltiple asintomático: recomendaciones del Grupo Español de Mieloma
Mateos, M., Bladé, J., Lahuerta, J. J., & Miguel, J. F. S. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.02.012 · Cited by 4
Advances in the management of asymptomatic myeloma
Mateos, M. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000121 · Cited by 4
“homogeneously diagnosed according to IMWG criteria and for whom long-term follow-up data were available [19].”
Zhao, J., Wang, M., He, P., Chen, Y., Wang, X., & Zhang, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.11321 · Cited by 5
“In general, MM is characterized by multi-step stages, including an indistinguishable early stage called monoclonal gammopathy of undetermined significance (MGUS) and an intermediate stage called smoldering MM (5) Ultimately, MM progresses to symptomatic plasma neoplasms, including intramedullary multiple myeloma and e…”
BackgroundHow We Manage Smoldering Multiple Myeloma
Romano, A., Cerchione, C., Conticello, C., Martinelli, G., & Raimondo, F. D. (2020) · Hematology Reports · doi:10.4081/hr.2020.8951 · Cited by 4
MyeloDB: a multi-omics resource for multiple myeloma
Kumar, A., Kumar, K. V., Kundal, K., Sengupta, A., Sharma, S., Kunjulakshmi, R., & Kumar, R. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01280-0 · Cited by 4
“An advanced stage of MGUS, which is also asymptomatic, called SMM, can progress to MM at a rate of 10% per year (first 5 years following diagnosis), 3% per year over the next 5 years, and 1.5% per year after that (Kyle et al. 2007; Rajkumar et al. 2013).”
InfluentialUtilisation of s FLC assays – how well do we comply with guidelines?
Phillips, D. P., Talaulikar, D., Hawkins, C. A., & Hickman, P. E. (2012) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12022 · Cited by 4
“If then stable, monitor every 6–12 months 2010 Guidelines – based on widely adopted 2007 NEJM study recommending monitoring at 2–3 months post-diagnosis, then every 4–6 months [50] MGUS of moderate to high risk requires monitoring at 6 months post-diagnosis and then annually 2010 Guidelines – prior recommendation was…”
BackgroundRole of thalidomide in previously untreated patients with multiple myeloma
Musto, P., D’Auria, F., Pietrantuono, G., Bringhen, S., Morabito, F., Raimondo, F. D., Pozzi, S., Sacchi, S., Boccadoro, M., & Palumbo, A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.10.1569 · Cited by 5
Musto, P., & Rocca, F. L. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1753502 · Cited by 4
“The risk of progression to overt, symptomatic MM for SM is about 10% per year during the first 5 years and then progressively decreases [72].”
BackgroundEvolving Concepts in the Diagnosis and Staging of Multiple Myeloma
Hillengaß, J. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.5041 · Cited by 4
Smoldering multiple myeloma 40 years later: a story of unintended disease
Yavorkovsky, L. L. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1875815 · Cited by 4
“was equated with asymptomatic myeloma [3,6] that, in”
BackgroundPositron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting
Ferrarazzo, G., Chiola, S., Capitanio, S., Donegani, M. I., Miceli, A., Raffa, S., Tagliafico, A. S., Morbelli, S. D., & Bauckneht, M. (2021) · Diagnostics · doi:10.3390/diagnostics11020230 · Cited by 4
“In some cases, an intermediate phase, defined as smoldering multiple myeloma (SMM) is also described [2].”
BackgroundIsola, I., Moreno, D. F., Moga, E., Mena, M.-P., Tovar, N., Rodríguez‐Lobato, L. G., Oliver‐Caldés, A., Salgado, M. C., Brasó‐Maristany, F., Yagüe, J., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04653-2 · Cited by 5
“Isotype-matched immunoparesis (IMI) was defined by the HLC assay as a concentration below the lower limit of the reference range of the polyclonal pair with the same isotype as the M-protein (e.g., IgGκ suppression in a patient with IgGλ SMM).”
BackgroundInfluentialSmoldering multiple myeloma: biology, clinical manifestations and management
Nsiala, L., Bobin, A., Lévy, A., Gruchet, C., Sabirou, F., Gardeney, H., Cailly, L., Manier, S., Moya, N., Tomowiak, C., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1992615 · Cited by 4
Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
Sklavenitis‐Pistofidis, R., Getz, G. A., Ghobrial, I. M., & Papaioannou, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961421 · Cited by 4
“5% of people over the age of 40 years have SMM (6); their progression risk follows a logistic growth model with a yearly risk of 10% for the first 5 years and a gradual decrease in risk after that until an MGUSlike slope is reached (7).”
BackgroundSerum Free Light Chain Quantification Testing: Comparison of Two Methods for Disease Monitoring
Singh, G., Whitaker, B. M., Wu, A. H. B., Xu, H., & Bollag, R. J. (2022) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfac068 · Cited by 4
Willrich, M. A. V., Murray, D. L., Rajkumar, S. V., Bryant, S. C., Larson, D. R., Pazdernik, V., Snyder, M. R., Kyle, R. A., & Dispenzieri, A. A. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00722-5 · Cited by 4
“From the original cohort of 586 of newly diagnosed SMM patients seen at the Mayo Clinic from 1976 to 2011 (2, 3) with authorization to review their medical records for research purposes, we excluded (n=302) those patients: 1) with no remaining stored serum sample within 30 days of SMM diagnosis; or 2) who had received…”
BackgroundSelf-citationŁuczkowska, K., Kulig, P., Rusińska, K., Baumert, B., & Machaliński, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316780 · Cited by 4
Early Detection of Precursor Diseases of Multiple Myeloma
O’Donnell, E., Borden, B. A., & Ghobrial, I. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.03.003 · Cited by 4
Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates
Kristinsson, S. Y., Landgren, O., & Rajkumar, S. V. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181c60f08 · Cited by 4
Self-citationShah, R., Shah, N. N., Shah, A. K., & Mehta, A. N. (2014) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2014.11929039 · Cited by 6
“It has been reported that patients with smoldering multiple myeloma (SMM) will progress to symptomatic myeloma or amyloidosis at an approximate rate of 10% per year for the fi rst 5 years, 3% per year for the next 5 years, and 1% to 2% per year for the following 10 years (4).”
BackgroundClassification of Plasma Cell Neoplasms
Yohe, S. L. (2015) · Springer eBooks · doi:10.1007/978-3-319-10918-3_4 · Cited by 4
“Some patients may have stable disease for long periods without progression and will not require treatment [17].”
BackgroundInfluentialQuan, L., Li, Q., Ma, C., Cao, X., & Sun, C. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2560679 · Cited by 3
“Previous studies have shown that the progression rate of SMM to MM is around 10% annually per year over the first 5 years after diagnosis, decreasing to 3% per year over the next 5 years, and further dropping to 1% per year thereafter [3].”
Metadata
- Authors
- Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2582-2590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974983065
- Cited by
- 921
- References
- 25
- Citations by year
- 2026: 34 · 2025: 57 · 2024: 62 · 2023: 48 · 2022: 56 · 2021: 69 · 2020: 70 · 2019: 45 · 2018: 49 · 2017: 37 · 2016: 55 · 2015: 46 · 2014: 50 · 2013: 56 · 2012: 42
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 107 476, CA6 2242, R01CA107476, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, asymptomatic multiple myeloma, amyloidosis, prognostic factors, risk stratification, clinical course
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amyloidosis, Antibodies, Monoclonal, Biopsy, Bone Marrow Cells, Bone Marrow Examination, Female, Humans, Male, Middle Aged, Multiple Myeloma, Plasma Cells, Prognosis, Risk Factors, Cohort Studies, Disease Progression, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.